or
forgot password
  • cancer clinical trials in fort scott, KS

  • S9925: Collecting and Storing Samples From Patients With Lung Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Lung Cancer
    Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Carcinoma of Unknown Primary
    Dinaciclib in Treating Patients With Stage IV Melanoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Mucosal Melanoma, Nodular Malignant Melanoma, Recurrent Melanoma, Stage IV Melanoma, Superficial Spreading Malignant Melanoma
    Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Stage IV Prostate Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
    Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
    Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
    Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma
    Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Chemotherapeutic Agent Toxicity, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Pain, Peripheral Neuropathy, Primary Peritoneal Cavity Cancer
    Home-Based Programs for Improving Sleep in Cancer Survivors
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Cancer Survivor, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders
    Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Colorectal Cancer, Precancerous Condition
    Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
    Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Lung Cancer
    Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Cognitive/Functional Effects, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Breast Cancer
    Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Anaplastic Carcinoma of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
    S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
    Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
    Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Breast Cancer
    Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Kidney Cancer
    Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Breast Cancer
    Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma
    Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer
    Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Diarrhea, Gastrointestinal Complications, Unspecified Adult Solid Tumor, Protocol Specific
    Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Adenoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Adenoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Adenoma, Pancreatic G-cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Recurrent Pancreatic Cancer, Somatostatinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
    Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Breast Cancer
    Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
    Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
    Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer
    Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Breast Cancer, Depression, Fatigue, Sleep Disorders
    S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Prostate Cancer
    S0820, Adenoma and Second Primary Prevention Trial
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Colorectal Neoplasms
    PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Lymphoma
    Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Anxiety Disorder, Fallopian Tube Cancer, Fatigue, Nausea and Vomiting, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Cancer
    S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
    Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Breast Cancer, Cancer Survivor, Hot Flashes
    Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma
    Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
    Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Cervical Cancer, Lymphedema, Sexuality and Reproductive Issues
    Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Neurofibrosarcoma, Chondrosarcoma, Endometrial Stromal Sarcoma, Mast Cell Sarcoma, Metastatic Adult Malignant Fibrous Histiocytoma of Bone, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Adult Malignant Fibrous Histiocytoma of Bone, Recurrent Adult Soft Tissue Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
    Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
    Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Childhood Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
    Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
    Armodafinil in Reducing Cancer-Related Fatigue in Patients With Glioblastoma Multiforme
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Fatigue
    Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
    High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Melanoma (Skin)
    Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Recurrent Adult Acute Lymphoblastic Leukemia
    Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Recurrent Melanoma, Stage IV Melanoma
    Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009)
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
    Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Lymphoma
    Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Pancreatic Cancer
    Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
    Cancer Center of Kansas - Fort Scott
    Fort Scott, Kansas 66701
    Brain and Central Nervous System Tumors